Topotecan
- TRADE NAME: Hycamtin (GSK)
- INDICATIONS: Metastatic ovarian carcinoma
- CLASS: Antineoplastic / anticancer agent (see also Immune checkpoint inhibitor), Topoisomerase 1 inhibitor
- HALF-LIFE: 3–6 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Atorvastatin, Darunavir, Gefitinib, Lapatinib, Oxaliplatin, Pantoprazole, Safinamide, Sofosbuvir & Velpatasvir
PREGNANCY CATEGORY: D
BONE MARROW SUPPRESSION
See full prescribing information for complete boxed warning.
Please login to see the rest of this drug profile
SKIN.
HAIR.
NAILS.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
RENAL.
RESPIRATORY.
OTHER.
Page last updated 07/31/2023
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric